Dosimetry data from the Phase I expansion cohort of Radspherin® in colorectal cancer patients to be presented at the 2022 EANM Annual Meeting

The aim of this study was to estimate the absorbed doses to normal tissues for patients injected intraperitoneally with a suspension of radium-224 adsorbed in calcium carbonate microparticles (224Ra-CaCO3-MP) for treating peritoneal carcinomatosis originating from colorectal cancer.

Organiser: EANM 2022

CCIB – Centre de Convencions Internacional
de Barcelona / Barcelona International
Convention Centre
Hall 111

e-Poster Presentation Session 11 – Dosimetry

Committee: Dosimetry – Novel Tracers and Computer-Based Modelling

Date: 18 October 2022
Program: Program

Anders Månsson

Chief Executive Officer

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.